International Journal of Molecular Sciences · 2024 · 32 citations · 57 references
Life SciencesInfectious DiseasesPharmacologyDrug DiscoveryInnate ImmunityVirologyAntiviral AgentsAntiviral PharmacologyAntiviral TherapyEnzyme InhibitionViral InfectionsViral PathogenesisAntiviral Drug DesignAntiviral TherapeuticsOrthosteric Binding SitesOrthosteric InteractionsProtease InhibitorsViral Protease FunctionViral Protease InhibitionViral Proteases
In the global pandemic scenario, dengue and zika viruses (DENV and ZIKV, respectively), both mosquito-borne members of the flaviviridae family, represent a serious health problem, and considering the absence of specific antiviral drugs and available vaccines, there is a dire need to identify new targets to treat these types of viral infections. Within this drug discovery process, the protease NS2B/NS3 is considered the primary target for the development of novel anti-flavivirus drugs. The NS2B/NS3 is a serine protease that has a dual function both in the viral replication process and in the elusion of the innate immunity. To date, two main classes of NS2B/NS3 of DENV and ZIKV protease inhibitors have been discovered: those that bind to the orthosteric site and those that act at the allosteric site. Therefore, this perspective article aims to discuss the main features of the use of the most potent NS2B/NS3 inhibitors and their impact at the social level.
57
Nicholas S. Heaton, Rushika Perera, Kristi L. Berger et al. · Proceedings of the National Academy of Sciences · 2010 · 562 citations · Full text
Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor
Jian Lei, Guido Hansen, Christoph Nitsche et al. · Science · 2016 · 378 citations · Full text
Jun Li, Siew Pheng Lim, David Beer et al. · Journal of Biological Chemistry · 2005 · 249 citations · Full text